The disclosure relates to the use of polygodial which is a drimane-type sesquiterpene dialdehyde compound also known as , tadeodal or tadeonal which is represented by the structural formula shown herein, having chemical name: (1R,4aS,8aS)-5,5,8a-Trimethyl-1,4,4a,6,7,8-hexahydronaphthalene-1,2-dicarboxaldehyde, which has the ability to at least partially inhibit replication of a viral genome, in the manufacture of a medicament for the treatment or prevention of a viral infection, or a disease caused by the viral infection.
